|Bid||0.7601 x 1100|
|Ask||0.7773 x 1400|
|Day's range||0.7425 - 0.7970|
|52-week range||0.6000 - 3.6800|
|Beta (5Y monthly)||2.09|
|PE ratio (TTM)||N/A|
|Earnings date||28 Mar 2022 - 01 Apr 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||18 Dec 2012|
|1y target est||5.60|
We can readily understand why investors are attracted to unprofitable companies. For example, although...
HENDERSON, Nev., June 02, 2022--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in two upcoming investor conferences:
HENDERSON, Nev., May 26, 2022--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced additional exploratory data for poziotinib in non-small cell lung cancer (NSCLC) patients harboring HER2 exon 20 insertion mutations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from June 3-7.